Pembrolizumab is a medicine used to treat different types of cancer. In this study, researchers want to see if people with cancer prefer getting pembrolizumab as a shot under the skin (called subcutaneous) with another substance, hyaluronidase, or through a needle in the vein (intravenous). This study does not test if one way is better than the other, it only asks for people’s preferences.
- This study involves people with early stage or advanced solid tumors like melanoma, renal cell carcinoma, and non-small cell lung cancer.
- Participants must be healthy enough, with a life expectancy of at least 3 months.
- People who have had certain treatments or conditions, like recent surgery or active infections, cannot join.
The study does not involve any new treatments, just different forms of the same treatment, and there are no tests to see if one is better at fighting cancer. If you qualify and decide to join, you will share which method you prefer. This might help doctors understand how to make treatments more comfortable for patients in the future.
How understandable was the trial content above?
Hard to understand
Easy to understand